Abolis Biotechnologies is a French synthetic biology company specializing in fermentation-based production of bio-based ingredients and specialty chemicals. It engineers microbial strains and metabolic pathways to enable sustainable manufacturing of target molecules that can substitute petrochemical or animal-derived inputs.
The company’s work spans strain design and optimization, lab-to-pilot bioprocess development, scale-up, and technology transfer with industrial partners. Abolis serves markets including cosmetics, flavors and fragrances, nutrition, healthcare, and industrial applications, providing contract R&D as well as developing proprietary molecules. Using metabolic engineering, high-throughput screening, and data-driven design–build–test–learn workflows, it supports the introduction of new bio-based products and the improvement of cost, performance, and environmental profiles for existing ingredients.